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donors on GvHD and relapse development or posttransplant mor-
tality.
CONCLUSION: The use of RIC is probably associated with
less expressed inﬂammation (e.g. gastrointestinal tract) and in spite
of allele G presentation (including homozygous form) it might lead
to lower level of IL-6 and lower incidence of severe GvHD. In
contradistinction to previously published analyses of patients al-
lografted after standard myeloablative regimens, the assessment of
this cohort with the frequent use of RICs (59%) failed to prove
IL-6 gene polymorphism to be a universal predictor of posttrans-
plant outcome in such circumstances.
Supported by the Ministry of Education grant MSM
6198959205.
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MAJOR ABO BLOOD GROUP MISMATCH INCREASES THE RISK FOR
GRAFT FAILURE AFTER UNRELATED DONOR HEMATOPOIETIC STEM
CELL TRANSPLANTATION
Remberger, M.1, Watz, E.2, Ringde´n, O.1, Mattsson, J.1, Shanwell, A.2,
Wikman, A.2 1Karolinska Institutet, Clinical Immunology, Karolinska
University Hospital, Stockholm, Sweden; 2Transfusion Medicine, Karo-
linska University Hospital, Stockholm, Sweden.
Two hundred and twenty-four patients with leukemia trans-
planted with an unrelated donor between 1991 and 2003 at Karo-
linska University Hospital were analyzed according to association
between graft failure and ABO, RhD, MNSs and Kidd blood group
antigen compatibility. Median age was 29 years (range 0-55). ).
Two hundred patients and donor pairs were HLA-A, -B, and –DR
identical, and 24 patients had an allele-level mismatched donor
Conditioning consisted of TBI or busulfan-based myeloablative
conditioning. All patients received ATG. A bone marrow graft was
given to 152 patients and 72 patients received peripheral blood
stem cells. Most patients received GVHD prophylaxis with CsA
and MTX.
Results: 135 (60%) patients received an ABO mismatched graft
and 89 received an ABO matched graft. Of the mismatched grafts,
67 (30%) were major mismatched and 68 (30%) minor mis-
matched. A bidirectional mismatch was found in 16 (7%) cases.
Graft failure (GF) was seen in 6 (2.7%) patients. In the multivariate
analysis major ABO mismatch (OR 14.9, 95% CI 2.01-110,
p0.008) and HLA-allele mismatch (6.42, 1.19-34.8, p0.03) was
signiﬁcantly associated to GF. In patients with and without major
ABO mismatch the incidence of GF was 7.5% (5/67) and 0.6%
(1/157)(p0.02), respectively. In patients with and without HLA
allele-level mismatch, the incidence of GF was 8.3% (2/24) and
2.0% (4/200)(p0.09).
Conclusion: Using an ABO major mismatched graft increases
the risk for graft failure after unrelated donor HSCT.
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FLUDARABINE – ORAL BUSULFAN MYELOABLATIVE CONDITIONING
FOR ALLOGENIC PERIPHERAL STEM CELL TRANSPLANTATION. A SIN-
GLE CENTER EXPERIENCE IN COLOMBIA
Rosales, C.1, Abello, V.1, Rosales, E.1, Esguerra, H.1, Linares, A.1
1Clı´nica de Marly, Bogota´, Colombia.
A regimen of busulfan and cyclophosphamide was standard con-
ditioning regimen for allogeneic PBSC in our center for the last 10
years. To reduced toxicity related to high dose cyclophosphamide,
we are using a regimen of ﬂudarabine and oral busulfa´n.
Here we report clinical outcome in the ﬁrst 11 patients treated.
The conditioning regimen consisted of 30 mg/m2 intravenous
ﬂudarabine daily, day -5 to -2, and oral busulfan given at 1 mg/kg
4 times a day every 6 hours from day -5 to -2. Cyclosporine and
methotrexate were used for prophylaxis of GVHD in 9 patients
and Cyclosporine plus mycophenolate in 2.
Diagnoses were: AML in 5; MDS, NHL, ALL, NPH 1 each, and
CML in 2. The median patient age was 40 years (range, 17-59
years). Mobilized blood stem cells were obtained from HLA-
compatible siblings. Engraftment was achieved in all but one pa-
tient, who had high risk MDS, received a second transplant after
loosing the ﬁrst graft a year before, and died on day 34. At a
median follow up of 3.5 months (range 5.3-1.25) all other patients
are alive (day 100 transplant related mortality 7%). The median
time for neutrophil and platelet recovery were 10.9 (min 7, max
13) and 12 (min 0, max 15) days. There was no cardiac toxicity
and hemorrhagic cystitis. Grade 1-2 and grade 3 mucositis oc-
curred in 45% and 27% respectively. Of 10 evaluable patients 7
had acute GVHD grade 1-2 and 1 grade 3. 70% of patients became
CMV and received pre-emptive therapy.
Fludarabine – oral busulfan has been well tolerated in standard
conditioning regimen versus cyclophosphamide – oral busulfan,
but longer follow up is needed to establish deﬁnitive conclu-
sions.
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REDUCED RISK OF RELAPSE IN PEDIATRIC PATIENTS AFTER DOUBLE
UNIT CORD BLOOD TRANSPLANTATION? A SINGLE INSTITUTION EX-
PERIENCE
Rosenthal, J.1, Bolotin, E.1, Pawlowska, A.1, Falk, P.1, Hitt, D.1,
Forman, S.1 1City of Hope National Medical and Research Center,
Duarte, CA.
Unrelated umbilical cord blood transplantation (UCBT) has be-
come a standard therapeutic option for pediatric patients who may
beneﬁt from hematopoietic stem cell transplantation but lack an
adequate HLA-identical related donor. UCBT has the advantages of
rapid availability and presumably lower risk of severe, acute GVHD
despite donor-recipient HLA disparity. Double-unit UCBT
(DUCBT) extends access to transplantation for patients who were
previously disqualiﬁed on the basis of low cell dose in a single unit.
Recent studies report high engraftment rate, acceptable rates of severe
acute GVHD and acceptable rates of transplantation-related mortal-
ity with DUCBT. (Barker Blood. 2005;105:1343-1347). It is un-
known, however, whether patients with advanced hematological ma-
lignancies and patients with severe co-morbidities would beneﬁt from
DUCBT. DUCBT was given to 7 patients with advanced hemato-
logical malignancies (AML,n3, refractory n1, 2CR n1, 3CR
n1, ALL, n4; 1CR Ph n 1, 2CR Ph n1, both MRD,
2CR n2). The males/female ratio was 5/2. Ages were 5.2-15 yrs
(median 14 yr). Five of seven were non-Caucasian (71%). Co-mor-
bidities included invasive fungal infection (n3), acute pancreatitis
(n1), and bulbar paralysis (n1). Conditioning regimes were FTBI
and melphalan (n3) and ﬂudarabine with melphalan (n4). Myeloid
engraftment occurred in all patients. The median time to an absolute
neutrophil count500 was 34 days (range 26-74 days). Three patients
remained platelet transfusion dependent after day 100. In the remain-
ing 4 patients the median time to a platelet count 20,000 unsup-
ported were 51 days (range 44-69 days). All patients (100%) experi-
encedGrades II-III acuteGVHD.There were no patients withGrade
IV GVHD and no deaths from acute GVHD. Four patients devel-
oped extensive chronic GVHD of the skin only. The 100 day trans-
plant related mortality was 0%. One patient died on day  200 from
respiratory failure secondary to multiple recurrent viral infections
(CMV, Parainﬂuenza type 3, and herpes simplex virus). None of the
patient suffered relapse. The disease-free survival is 80% with a
median day 405 post transplant (range 173-1126). The observation
that DUCBT may be associated with a reduced risk of relapse in
patients with high-risk leukemia deserves further evaluation. Larger
studies will be needed to conﬁrm the clinical observation and inves-
tigate what are the potential mechanisms by which DUCBT could
mediate an anti-leukemic effect.
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UMBILICAL CORD BLOOD TRANSPLANTATION USING NON-MYELOAB-
LATIVE CONDITIONING: THE MEXICAN EXPERIENCE
Mancias-Guerra, C.1, Ruiz-Delgado, G.J.1, Manzano, C.2,
Diaz-Hernandez, M.A.2, Tarin-Arzaga, L.C.1, Gonzalez-Llano, O.1,
Calderon, E.D.3, Gomez-Almaguer, D.1, Ruiz-Arguelles, G.J.2 1Hos-
pital Universitario de Nuevo Leon, Monterrey, NL, Mexico; 2Centro de
Hematologia y Medicina Interna de Puebla, Puebla, PUE, Mexico;
3CordMX. Centro Nacional de la Transfusion Sanguı´nea, Mexico City,
DF, Mexico.
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Twenty eight both children and adults were grafted with
allogeneic umbilical cord blood cells (UCB), 15 males and 13
females. Seven patients were grafted because a non-malignant
condition and 21 for a malignant disease. The median age was 8
years (range 4 months – 72 years). Ten UCB were obtained
from Mexican cord bloods banks, ﬁve cords were from compat-
ible siblings and the remaining 13 cords were obtained from
abroad. Median time to recover  0.5  109/ L granulocytes
was 24 days (range 8 – 32 days), whereas median time to recover
 20  109/ L platelets was 26 days (range 12 – 50 days) Twelve
recipients never engrafted and recovered subsequently endoge-
nous hematopoiesis. The non-engraftment rate was signiﬁcantly
higher in patients allografted for benign conditions (71%) than
in those allografted for malignant conditions (28%). The me-
dian overall post-transplant survival (SV) was 33 months and the
73-months overall SV was 39%. The cumulative incidence of
grade II–IV acute GVHD and grade III–IV GVHD for the
entire cohort of patients were 14% and 7%, respectively. Addi-
tional studies are needed to deﬁne if non-myeloablative condi-
tioning is preferable over conventional conditioning in the case
of UCB allografting.
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CORRELATES AND OUTCOME OF ABSOLUTE LYMPHOCYTE COUNT
(ALC) ON DAY 30 POST ALLOGENEIC STEM CELL TRANSPLANTATION
(SCT) FOR TREATMENT OF AML
Saliba, R.M.1, Komanduri, K.1, Giralt, S.1, de Souza, J.1, Patah, P.A.1,
Oran, B.2, Rondon, G.1, Couriel, D.P.1, Champlin, R.1, de Lima, M.1
1University of Texas M.D. Anderson Cancer Center, Houston, TX;
2Boston University Medical Center, Boston, MA.
It has been proposed that lymphocyte recovery is associated
with transplant outcomes. We evaluated the prevalence, corre-
lates and outcome of ALC 500109/L on day 30 post SCT in
130 consecutive high-risk AML patients (pts), who received
HLA-matched unmanipulated PBSCT from a sibling donor(s-
ibling/PB, n69) or BM from a matched unrelated donor
(MUD/BM, n61) between 1996 and 2006, and who were alive
and in complete remission on day 30 post SCT. Conditioning
regimen was FM (ﬂudarabine 25-30mg/m2 for 4-5 days and
melphalan 100-180mg/m2), GVHD prophylaxis was tacrolimus
and methotrexate in 92% of pts. Results: ALC count on day 30
post SCT was signiﬁcantly lower in pts who were diagnosed
with grade II-IV acute GVHD within 30 days post SCT (n21,
median 250 109/L ) compared with grade 0-I (n109, median
650 109/L ), p0.001. Excluding pts with grade II-IV acute
GVHD, 37% of 109 patients had 500 109/L ALC on day 30.
Signiﬁcant factors associated with ALC500109/L on univar-
iate analysis included presence of circulating blasts at time of
SCT, CMV antigenemia within 30 days post SCT, and platelet
count below the median on day 30 post SCT. There was a
strong trend for lower count associated with age 57 years
(median), a higher than the median number of chemotherapy
regimens prior to SCT, and MUD/BM graft. There was no
association between ALC and gender or time to ALC
200109/L or 500109/L. These ﬁndings were consistent when
analysis was stratiﬁed by type of graft (sibling/PB and MUD/
BM) and on multivariate analysis with the exception of lower
statistical signiﬁcance for disease status at SCT. With a median
follow-up of 29 months, a landmark analysis starting at day 30
post SCT showed a signiﬁcantly higher rate of mortality and
non relapse mortality (NRM) at 3 years for pts with
ALC500109/L in recipients of a sibling/PB graft (HR OS
2.6, p 0.02 ; (HRNRM3.7, p 0.03)), but not in recipients of a
MUD/BM graft (HROS 1.2, p 0.7; HRNRM 1.3, p 0.6). There
was a trend for a higher rate of grade II-IV acute GVHD after
day 30 in the ﬁrst group (HR2.1, p 0.2) but not in the later
(HR0.6, p 0.3). There was no impact on the rate of disease
progression or chronic graft versus host disease irrespective of
the type of graft. Conclusion: In AML pts, pre- and post-
transplant factors are correlated with low ALC on day 30 post
SCT which in turn is associated with higher mortality in recip-
ients of sibling/PB transplant.
Predictors of ALC on day 30 post SCT
N
%ALC<
500109
Univariate
OR p
Multivariate
OR p
Grade II-IV aGVHD 21 76% 5.5 0.002
Grade 0-I aGVHD 109 37%
Excluding grade II-IV
aGVHD
Type of graft
sibling/PBSC 61 33%
MUD/BM 48 42% 1.5 0.3 2.1 0.1
Dose of Melphalan (mg/
m2)
100 20 25% 0.5 0.2
140/180 89 39%
Age (years)
<57 63 30%
>57 46 46% 1.9 0.09
Disease status at SCT
CR/no CR no CB* 76 29%
No CR / CB 32 53% 2.8 0.02 1.9 0.2
Lines of prior
chemotherapy lines
<median 71 31%
>median 38 47% 2 0.09
CMV antigenemia by
day 30
Positive CMV
antigenemia 20 15% 0.2 0.03 0.1 0.01
No CMV antigenemia 88 42%
Platelet count on day 30
<median 54 48% 2.7 0.015 4.2 0.01
>median 55 25%
Time to ALC 200109/L
<median 37 38% 1.1 0.9
>median 72 36%
**Time to ALC
500109/L
<median 41 32% 0.9 0.8
>median 58 31%
*CB: Circulating blasts;**evaluated in patients who recovered ALC
500109/L within 30 days
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ALLOGENEIC HEMATOPIETIC CELL TRANSPLANTATION IN MYELOFI-
BROSIS WITH MYELOID METAPLASIA – LESSONS FROM SINGLE CEN-
TER RESULTS
Baurmann, H.1, Collenbusch, F.1, Thiede, C.2, Burlakova, I.1,
Schleuning, M.1, Schwerdtfeger, R.1 1Deutsche Klinik fuer Diagnostik,
Wiesbaden, Germany; 2Carl-Gustav-Carus University of Dresden,
Dresden, Germany.
Objective: Myeloﬁbrosis with myeloid metaplasia (MMM) is a
clonal myeloproliferative disorder of later life not generally con-
sidered for allogeneic haematopoietic cell transplantation (allo-
HCT) until recently. The natural course of the disease varies
greatly but is eventually fatal in all. We present the results of 35
consecutive transplants for MMM during the last six years in our
institution. -Material andMethods: 25 males and 10 females with
primary (n29) and secondary MMM (n6) were grafted with
unmanipulated bone marrow (n21) or peripheral stem cells
(n14) from a related (n10) or unrelated (n25) donor. Median
(md) age was 51 (33-64) years. Ten patients (pts) had low, 15
intermediate and 10 high risk disease (Dupriez score 0, 1, 2). 28 pts
had a modiﬁed Charlson comorbidity index (CCI, Diaconescu et
al, Blood 104, 2004: 1550) of 0 to 2, seven one of 3 to 6. Karyo-
typing was successful in 29 pts and abnormal in 12. All but four pts
received intermediate intensity conditioning (TBI(8Gy)/Flud/Cy n
 21 or Bu(10)/Flud n  10). In all unrelated and two related
transplants rabbit ATG was added before grafting. - Results: All
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